Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Authors:

Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M and Hodgson R.

Publication type:

Journal article

Publication name:

Pharmacoeconomics

Citation:

Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M and Hodgson R. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017.

Link to publication ⟶

⟵ Back to Search Results